Home > Boards > US Listed > Medical - Drugs > Revive Therapeutics Ltd. (RVVTF)

We’re gonna run up to the initial ph

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
LT 1990 Member Profile
 
Followed By 4
Posts 146
Boards Moderated 0
Alias Born 11/16/20
160x600 placeholder
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 InvestorsHub NewsWire - 5/3/2021 9:32:33 AM
Revive inks research agreement to explore use of Bucillamine in treating severe COVID-19 Seeking Alpha - 5/3/2021 9:27:48 AM
Revive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury InvestorsHub NewsWire - 4/27/2021 9:51:20 AM
Revive files for FDA orphan drug status for psilocybin in traumatic brain injury Seeking Alpha - 4/27/2021 9:33:08 AM
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....cont InvestorsHub NewsWire - 4/22/2021 8:26:06 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 InvestorsHub NewsWire - 3/24/2021 9:15:00 AM
Revive Therapeutics provides update on late-stage Bucillamine study in COVID-19 Seeking Alpha - 3/24/2021 9:08:15 AM
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...Cont InvestorsHub NewsWire - 3/19/2021 7:56:39 AM
Revive Therapeutics posts positive data from pre-clinical psilocybin brain injury study Seeking Alpha - 3/19/2021 7:37:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont InvestorsHub NewsWire - 2/26/2021 9:01:27 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont InvestorsHub NewsWire - 2/26/2021 9:01:27 AM
Revive Therapeutics Acquires Unique Psilocybin Assets InvestorsHub NewsWire - 2/17/2021 9:53:14 AM
Revive Therapeutics acquires psilocybin assets for C$10M Seeking Alpha - 2/17/2021 9:38:20 AM
Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program InvestorsHub NewsWire - 2/11/2021 8:05:24 AM
Revive Therapeutics in Phase 3 clinical trial for COVID-19 treatment InvestorsHub NewsWire - 1/27/2021 8:13:52 AM
How Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain Injuries InvestorsHub NewsWire - 1/18/2021 9:51:54 AM
Revive Therapeutics Announces Research Collaboration with North Carolina State University InvestorsHub NewsWire - 1/14/2021 8:30:27 AM
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study InvestorsHub NewsWire - 12/31/2020 8:30:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine InvestorsHub NewsWire - 12/23/2020 9:57:14 AM
Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program InvestorsHub NewsWire - 12/22/2020 11:05:23 AM
Biotech Report; Upcoming FDA Reviews and Promising Pipelines InvestorsHub NewsWire - 12/22/2020 8:20:00 AM
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor InvestorsHub NewsWire - 12/3/2020 8:30:00 AM
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin InvestorsHub NewsWire - 11/12/2020 9:00:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 InvestorsHub NewsWire - 10/30/2020 1:39:31 PM
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds InvestorsHub NewsWire - 10/20/2020 10:58:17 AM
LT 1990   Monday, 02/15/21 11:18:26 PM
Re: None
Post # of 26358 
We’re gonna run up to the initial ph 3 update which will be a good one as it’s been nearly two months in another 10 days. Shorts can’t cover as the only ask walls are the ones they’re putting up in hopes of getting some shares to cover. Shares held very tight. Those confused and wondering if there will be another placement. There won’t. 23 million + 4 million gives the company 27 ish million in cash on hand right now. Warrants will bring in another 43 million in cash.... give or take. that’s plenty of cash. Cannacord will be doing the placements behind the scene. You won’t even know when they happens unless you watch level 2 and look for the sales running through from cannacord in chunks to other houses. Fully diluted our float is under 400 million. Revive is awake, it’s hangryyy and it’s about to chew up that damn ask wall like no ones business. Catalysts... 1) EUA filing and trial update re enrolment etc, 2) EUA approval 3) nasdaq uplisting 4) govt funding? 5) big Pharma partnership 6) orders and sales from the states and the world 7) approvals from other countries, Canada likely first.

We have a ton of catalysts and that’s not to forget the huge pipelines related to the mushrooms and Autoimmune
Hepatitis.

See you at the bell ;) let’s get it

Shorts ... praying you burn like Melvin capital. Lol shorties days numbered everywhere, and this is a great company with great potential, not a bankrupt theatre company. The whales have shown up and along with new retail and longs not selling, it’s time to squeeze.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences